The development compound QXT-101 from Qx Therapeutics has been granted fast-track designation by the FDA for the treatment of Pulmonary Graft Dysfunction (PGD) following lung transplantation.
PGD of the transplanted human lung is a form of acute lung injury occurring after surgery. It is a major cause of early morbidity and mortality after lung transplantation and a potential risk factor for long-term post-transplant survival. Currently, there is no treatment for this condition, and it represents a highly unmet medical need.